Examinetics, Inc. – Trademark Portfolio
Entity Type: 03
Examinetics, Inc. owns a portfolio of 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), including well-known marks such as X, XM, SALUX, EXAMINETICS, and XM SOLUTIONS. Of these, 7 are registered and 1 is pending. The portfolio spans 4 Nice Classification classes, led by Class 35 (Advertising & Business) and Class 42 (Computer & Scientific). Headquartered in Overland Park, KS.
Suite 400
10561 Barkley Place
Overland Park, KS 66212
Showing of trademarks Trademarks
Trademark Classifications
Examinetics, Inc.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Advertising; business management; business administration; office functions
Scientific and technological services; industrial analysis and research services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does Examinetics, Inc. have?
Examinetics, Inc. has 10 U.S. trademarks filed with the USPTO. Of these, 7 registered, 1 pending, 1 abandoned, 1 cancelled.
What trademark classes does Examinetics, Inc. file in?
Examinetics, Inc. files trademarks across 4 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 10 (Medical Apparatus). Class 35 covers advertising; business management; business administration; office functions.
What are Examinetics, Inc.'s most well-known trademarks?
Examinetics, Inc.'s registered trademark portfolio includes well-known marks such as X, XM, SALUX, EXAMINETICS, and XM SOLUTIONS. These are among 7 currently registered trademarks in the portfolio.
What is Examinetics, Inc.'s trademark registration success rate?
Examinetics, Inc. has a 78% trademark registration rate, with 7 out of 9 resolved applications resulting in successful registration. Currently, 1 application is pending review.